Introduction: Who Should Undergo Diagnostics

Not every man needs to be tested for prostate cancer right away, but knowing when to seek diagnostics is important. Prostate cancer screening and diagnostic tests are recommended for certain groups of men who may be at higher risk or who are experiencing symptoms. Understanding who should be tested helps catch the disease early when treatment is most effective.^[1]

Most men start screening around age 55, though this can vary depending on individual risk factors. If you’re at a higher risk—for example, if you’re Black or of African ancestry, or if you have a close family member who had prostate cancer—your doctor may suggest starting screenings earlier, sometimes as young as age 40 or 45. Men with genetic changes linked to certain cancers, such as mutations in BRCA1 or BRCA2 genes, are also encouraged to discuss earlier testing with their healthcare provider.^[3][5]

If you notice any symptoms that could be related to prostate cancer, you should seek diagnostics promptly. These symptoms include frequent urination, especially at night, a weak or interrupted urine stream, trouble starting or stopping urination, pain or burning when urinating, blood in your urine or semen, or persistent pain in your lower back, hips, or chest. It’s important to understand that these symptoms can also be caused by other conditions, such as benign prostatic hyperplasia (an enlarged prostate that is not cancerous) or prostate infections, so diagnostic tests help determine the true cause.^[3][10]

In some cases, men with no symptoms may be diagnosed with prostate cancer through routine screening. Because prostate cancer often grows slowly and may not cause any noticeable problems for years, regular check-ups can detect the disease before it becomes more serious. Screening is especially valuable because early-stage prostate cancer rarely causes symptoms, and catching it early greatly improves the chances of successful treatment.^[5]

Diagnostic Methods: How Doctors Identify Prostate Cancer

Diagnosing prostate cancer involves several tests and procedures that help doctors determine whether cancer is present, how aggressive it is, and whether it has spread beyond the prostate. These methods are used both to detect cancer in its early stages and to distinguish prostate cancer from other conditions that affect the prostate.^[5]

Prostate-Specific Antigen (PSA) Test

The prostate-specific antigen test, or PSA test, is one of the most commonly used screening tools for prostate cancer. This is a blood test that measures the level of PSA, a substance produced by the prostate gland. When PSA levels in the blood are higher than normal, it may indicate prostate cancer. However, elevated PSA levels can also be caused by other conditions, such as an enlarged prostate, prostate infections, or inflammation of the prostate, so a high PSA result doesn’t always mean cancer is present.^[8][10]

Generally, the higher the PSA level, the more likely there is a problem with the prostate. But many factors can affect PSA levels, including age, race, and certain medical procedures or medications. Because of this, your doctor is the best person to interpret your PSA results and decide whether further testing is needed. Some men may have PSA levels checked regularly over time to see if the numbers are rising, which can be a sign of concern.^[8]

Digital Rectal Exam (DRE)

A digital rectal exam, or DRE, is a physical examination where a doctor inserts a gloved, lubricated finger into the rectum to feel the prostate gland through the rectal wall. The doctor checks for lumps, hard areas, or any abnormalities in the size or texture of the prostate. While the DRE can sometimes detect prostate cancer, it’s often used in combination with the PSA test for a more complete picture.^[10]

The DRE is a quick and simple procedure, though it may feel uncomfortable. It’s an important part of the diagnostic process because some prostate cancers don’t raise PSA levels but can still be felt during the exam. However, not all prostate cancers can be detected by a DRE, which is why other tests are also used.^[3]

Prostate Biopsy

If the PSA test or DRE suggests that prostate cancer might be present, the next step is usually a prostate biopsy. A biopsy is the only way to confirm a diagnosis of prostate cancer and determine its Gleason score, which indicates how aggressive the cancer is. During a biopsy, small samples of tissue are removed from the prostate gland using a needle. These samples are then examined under a microscope by a specialist.^[10]

The biopsy is typically guided by transrectal ultrasound, or TRUS, which uses sound waves to create an image of the prostate. This helps the doctor see where to take the tissue samples. In some cases, an MRI-TRUS fusion-guided biopsy may be used, which combines MRI imaging with ultrasound to target suspicious areas more precisely.^[5]

The Gleason score from the biopsy helps doctors understand how fast the cancer is likely to grow and spread. Lower Gleason scores suggest slower-growing cancers, while higher scores indicate more aggressive tumors. This information is crucial for deciding on the best treatment approach.^[10]

Magnetic Resonance Imaging (MRI)

An MRI scan uses magnets and radio waves to create detailed images of the prostate and surrounding tissues. MRI scans can help doctors see the size and location of a tumor, and they are especially useful for identifying areas that may need to be biopsied. Some MRI scans use a scoring system called PI-RADS (Prostate Imaging–Reporting and Data System) to rate how likely it is that cancer is present.^[5]

MRI is a non-invasive test, meaning it doesn’t involve inserting anything into the body or using radiation. It can provide valuable information to help guide treatment decisions, especially when combined with other diagnostic tools.^[3]

PSMA PET Scan

A PSMA PET scan is an imaging test used to find prostate cancer cells that have spread beyond the prostate gland into other parts of the body, such as the bones, lymph nodes, or organs. PSMA stands for prostate-specific membrane antigen, a protein found on prostate cancer cells. This scan uses a radioactive tracer that attaches to PSMA, making cancer cells visible on the scan.^[10]

This type of scan is especially helpful for detecting cancer that has spread and for planning treatment. It’s a newer technology that provides more detailed information than some older imaging tests.^[5]

Other Imaging Tests

In addition to MRI and PET scans, doctors may use other imaging tests to see if prostate cancer has spread. These include CT scans, bone scans, and ultrasound. Each test provides different information and helps doctors understand the extent of the disease. For example, a bone scan can detect whether cancer has spread to the bones, which is a common site for prostate cancer to spread.^[3]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or approaches to managing prostate cancer. To participate in a clinical trial, patients must meet certain criteria, and specific diagnostic tests are often required to determine eligibility. These tests help researchers ensure that the trial is appropriate for each participant and that the results will be meaningful.^[5]

One of the most common requirements for clinical trial enrollment is confirmation of a prostate cancer diagnosis through a biopsy. The biopsy results, including the Gleason score, help determine whether a patient’s cancer matches the type and stage being studied in the trial. Some trials focus on early-stage, localized cancer, while others are designed for advanced or metastatic prostate cancer (cancer that has spread to other parts of the body).^[10]

PSA levels are also frequently used as a qualification criterion. Trials may require that PSA levels fall within a certain range, or they may track changes in PSA levels during the study to measure how well a treatment is working. PSA testing is a standard tool for monitoring prostate cancer, so it’s commonly included in clinical trial protocols.^[5]

Imaging tests such as MRI scans, PSMA PET scans, CT scans, or bone scans may be required to assess whether the cancer has spread and to what extent. Trials for advanced prostate cancer often require evidence that the cancer has metastasized, while trials for localized disease may require imaging to confirm that the cancer has not spread beyond the prostate.^[10]

Some clinical trials also require genetic testing or biomarker testing. For example, trials studying targeted therapies may look for specific genetic mutations, such as changes in the BRCA1 or BRCA2 genes. Other trials may test for biomarkers in the blood or tissue that indicate how aggressive the cancer is or how likely it is to respond to a particular treatment. These tests help match patients to treatments that are most likely to benefit them.^[5]

Overall health assessments are also part of the qualification process. This includes blood tests to check kidney and liver function, heart tests, and evaluations of other medical conditions. Clinical trials want to ensure that participants are healthy enough to tolerate the treatment being studied and that other health issues won’t interfere with the results.^[3]